Califf Puts Weight Behind 'Sentinel' As Evidence-Generation System Of The Future
This article was originally published in Clinica
Executive Summary
US FDA Commissioner Robert Califf senses growing support from industry for the Sentinel system for tracking postmarket product performance using insurance claims and other data that is currently applied to pharmaceuticals, and is now moving into the device arena.